Adaptive Biotechnologies Corporation Common Stock
ADPT Real Time Price USDRecent trades of ADPT by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Ro Khanna House / D | Purchase $1,001 - $15,000 | N/A |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in ADPT holdings by institutional investors
Quarterly net insider trading by ADPT's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Jan 19, 2024 Issue: Health Issues
-
$30,000 Oct 16, 2023 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
-
$60,000 Jul 18, 2023 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
-
$70,000 Jan 18, 2023 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
-
$80,000 Oct 17, 2022 Issue: Medicare/Medicaid Budget/Appropriations Health Issues
-
$70,000 Jul 12, 2022 Issue: Budget/Appropriations Health Issues Medicare/Medicaid
-
$240,000 Mar 23, 2022 Issue: Medicare/Medicaid Health Issues
-
$190,000 Jan 21, 2022 Issue: None
-
$140,000 Oct 20, 2021 Issue: None
-
$120,000 Jul 15, 2021 Issue: None
-
$130,000 Apr 20, 2021 Issue: HEALTH ISSUES
-
$190,000 Jan 21, 2021 Issue: HEALTH ISSUES
-
$80,000 Oct 20, 2020 Issue: Health Issues Medicare/Medicaid
-
$50,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues
-
$30,000 Apr 20, 2015 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
ADPT Estimated quarterly lobbying spending
ADPT Revenue by Segment or Geography
New ADPT patent grants
-
Patent Title: Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing Sep. 30, 2025
-
Patent Title: Determining antigen-specific t-cells Jul. 08, 2025
-
Patent Title: T cell receptor sequences diagnostic for covid-19 and related compositions Apr. 01, 2025
-
Patent Title: Lyme disease-associated t cell receptor-related methods Apr. 01, 2025
-
Patent Title: Monitoring health and disease status using clonotype profiles Jan. 28, 2025
-
Patent Title: Synthetic strands for nucleic acid sequencing and related methods and systems Jan. 14, 2025
-
Patent Title: Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization Oct. 01, 2024
-
Patent Title: Method for studying v(d)j combinatory diversity Oct. 03, 2023
-
Patent Title: Synthetic strands for nucleic acid sequencing and related methods and systems Jul. 25, 2023
-
Patent Title: Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs) Jul. 19, 2022
-
Patent Title: Determining antigen-specific t-cells Mar. 01, 2022
-
Patent Title: Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements Feb. 22, 2022
-
Patent Title: Methods using randomer-containing synthetic molecules Feb. 15, 2022
-
Patent Title: Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization Nov. 23, 2021
-
Patent Title: Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing Jul. 20, 2021
-
Patent Title: Methods for diagnosing infectious disease and determining hla status using immune repertoire sequencing Jun. 29, 2021
-
Patent Title: Method of identifying human compatible t cell receptors specific for an antigenic target Jun. 22, 2021
-
Patent Title: Monitoring health and disease status using clonotype profiles Jun. 01, 2021
-
Patent Title: Methods of monitoring conditions by sequence analysis May. 11, 2021
-
Patent Title: Compositions and methods for measuring and calibrating amplification bias in multiplexed pcr reactions Jan. 19, 2021
-
Patent Title: Monitoring health and disease status using clonotype profiles Dec. 15, 2020
-
Patent Title: Monitoring health and disease status using clonotype profiles Sep. 01, 2020
-
Patent Title: Method for genotyping clonotype profiles using sequence tags Jan. 07, 2020
-
Patent Title: Monitoring health and disease status using clonotype profiles Dec. 31, 2019
-
Patent Title: Determining antigen-specific t-cells Oct. 08, 2019
-
Patent Title: Identification of antigen-specific b cell receptors Oct. 01, 2019
-
Patent Title: Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples Aug. 27, 2019
-
Patent Title: Random array sequencing of low-complexity libraries Aug. 20, 2019
-
Patent Title: Adaptive immunity profiling and methods for generation of monoclonal antibodies Jun. 18, 2019
-
Patent Title: Methods of monitoring conditions by sequence analysis Apr. 23, 2019
-
Patent Title: Methods of monitoring conditions by sequence analysis Apr. 02, 2019
-
Patent Title: Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture Apr. 02, 2019
-
Patent Title: Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization Mar. 05, 2019
-
Patent Title: Compositions and method for measuring and calibrating amplification bias in multiplexed pcr reactions Feb. 26, 2019
-
Patent Title: Diagnosis of lymphoid malignancies and minimal residual disease detection Nov. 21, 2017
-
Patent Title: Method for generating clonotype profiles using sequence tags Jul. 18, 2017
-
Patent Title: Rare clonotypes and uses thereof Dec. 27, 2016
-
Patent Title: Sequence analysis of complex amplicons Dec. 20, 2016
-
Patent Title: Monitoring health and disease status using clonotype profiles Dec. 06, 2016
-
Patent Title: Method of sequence determination using sequence tags Nov. 29, 2016
-
Patent Title: Detection and measurement of tissue-infiltrating lymphocytes Nov. 22, 2016
-
Patent Title: Monitoring health and disease status using clonotype profiles Aug. 16, 2016
-
Patent Title: Detection and quantification of sample contamination in immune repertoire analysis Jul. 19, 2016
-
Patent Title: Compositions and method for measuring and calibrating amplification bias in multiplexed pcr reactions Jun. 21, 2016
-
Patent Title: Monitoring immunoglobulin heavy chain evolution in b-cell acute lymphoblastic leukemia Jun. 14, 2016
-
Patent Title: Single cell analysis by polymerase cycling assembly May. 24, 2016
-
Patent Title: Quantification of adaptive immune cell genomes in a complex mixture of cells Mar. 08, 2016
-
Patent Title: Quantification of adaptive immune cell genomes in a complex mixture of cells Nov. 10, 2015
-
Patent Title: Quantification of adaptive immune cell genomes in a complex mixture of cells Nov. 10, 2015
-
Patent Title: Compositions and method for measuring and calibrating amplification bias in multiplexed pcr reactions Oct. 06, 2015
Federal grants, loans, and purchases
Estimated quarterly amount awarded to ADPT from public contracts
Recent insights relating to ADPT
Recent picks made for ADPT stock on CNBC
ETFs with the largest estimated holdings in ADPT
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $ADPT stock a Buy, Sell, or Hold?
- What is the price target for $ADPT stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $ADPT stock?
- Who owns the most shares of $ADPT stock?
- What funds own $ADPT stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ADPT Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
- Address Seattle, WA
- Market Cap 2.1 billion
- Employees 619
- Industrial Classification Biological Products, (No Disgnostic Substances)